Hollow fiber assay microtube array membrane (MTAM-HFA) for personalized anticancer drug screening in selection of concurrent chemoradiotherapy in oral squamous cell carcinoma.
12 affiliations
- 1Division of Oral and Maxillofacial Surgery, Department of Stomatology, Taipei Municipal Wanfang Hospital, Taipei, Taiwan.
- 2Department of Dentistry, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan.
- 3Institute of Oral Medicine and Materials, College of Medicine, Tzu Chi University, Hualien, Taiwan.
- 4Graduate Institute of Biomedical Materials and Tissue Engineering, Taipei Medical University, Taipei, Taiwan.
- 5Translational Autoinflammatory Disease Section (TADS), Laboratory of Clinical Immunology and Microbiology (LCIM), National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
- 6Department of Otolaryngology, Taipei Municipal Wanfang Hospital, Taipei, Taiwan.
- 7Department of Hematology-Oncology, Taipei Municipal Wanfang Hospital, Taipei Medical University, Taipei, Taiwan.
- 8International PhD Program for Cell Therapy and Regeneration Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
- 9Ph.D Program in Biotechnology Research and Development, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
- 10International Ph.D. Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.
- 11School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan.
- 12Division of Oral and Maxillofacial Surgery, Department of Dentistry, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
Abstract
Background/purpose
In Asia, oral squamous cell carcinoma (OSCC) are on the rise in part due to the consumption of betel nut in several regions. This clinical case study evaluated the application of the microtube array membrane-hollow fiber assay (MTAM-HFA) that was previously clinically demonstrated in the context of the selection of chemotheraputic agents as part of the treatment of concurrent chemoradiotherapy (CCRT) in OSCC.Materials and methods
In this double-blind cohort study, surgical samples from OSCC patients were retrieved and sent for screening of tumor response against a panel of chemotherapeutic agents (5-fluorouracil (5-FU), cisplatin, carboplatin and docetaxel). Screening outcomes were compared to the clinical outcome of patients receiving the same agents.Results
MTAM-HFA could predict clinical response of all 3 patients. In patient 1 and 2, MTAM-HFA screening predicted the chemotherapeutic agents accurately which was reflected in the clinical outcome of these respective patients where a significant and stable regression of tumor was observed. In patient 3, the MTAM-HFA screening revealed that 5-FU and cisplatin would exhibit limited anticancer effect. Clinically, after being administered a cocktail of docetaxel, cisplatin and 5-FU, the tumor regressed initially. However, tumor progression was noted after 2nd neoadjuvant chemotherapy. Anticancer drug resistance was later identified resulting in the need for multimodal approach.Conclusion
Overall, the outcomes were aligned with MTAM-HFA predictions, validating the ability to predict the anti-cancer effects of drugs. This highlights MTAM-HFA as a promising precision oncology system; with a larger prospective interventional clinical study planned for future validation.
Related
- Sequential chemoradiotherapy vs. radiotherapy alone or concurrent chemoradiotherapy after radical resection of stage IA2–IIA1 cervical cancer: a retrospective cohort study
- A Systematic Review and Meta-Analysis: Does Molecular Hydrogen Exert Radioprotective Effects Without Compromising the Antitumor Efficacy of Radiotherapy or Concurrent Chemoradiotherapy?
- Comparative Evaluation of Concurrent Carboplatin-Paclitaxel Versus Cisplatin-Etoposide Chemoradiotherapy in Unresectable Non-small Cell Lung Cancer: A Prospective Randomized Study
- Prediction Model for Detecting Active Pulmonary Tuberculosis in Patients With Head and Neck Cancer Prior to Concurrent Chemoradiotherapy
- Combined Active Bone Marrow‐Sparing Radiotherapy and Prophylactic PEG‐rhG‐CSF to Reduce Severe Neutropenia During Platinum‐Doublet Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer: A Phase II Trial
BibTeX
@article{chou2026hollow,
title = {{Hollow fiber assay microtube array membrane (MTAM-HFA) for personalized anticancer drug screening in selection of concurrent chemoradiotherapy in oral squamous cell carcinoma.}},
author = {Shan-Ju Chou and Po-Chih Hsu and Chee Ho Chew and Wan-Ting Huang and Amanda Lin Chen and Chen-Yin Yong and Chia-Che Wu and Chia-Lun Chang and Chien-Chung Chen and Kuan-Chou Lin},
journal = {Journal of dental sciences},
year = {2026},
month = oct,
doi = {10.1016/j.jds.2025.07.3514},
url = {https://europepmc.org/article/MED/42923691},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Hollow fiber assay microtube array membrane (MTAM-HFA) for personalized anticancer drug screening in selection of concurrent chemoradiotherapy in oral squamous cell carcinoma.
AU - Shan-Ju Chou
AU - Po-Chih Hsu
AU - Chee Ho Chew
AU - Wan-Ting Huang
AU - Amanda Lin Chen
AU - Chen-Yin Yong
AU - Chia-Che Wu
AU - Chia-Lun Chang
AU - Chien-Chung Chen
AU - Kuan-Chou Lin
PY - 2026
DA - 2026/10/01
JO - Journal of dental sciences
DO - 10.1016/j.jds.2025.07.3514
UR - https://europepmc.org/article/MED/42923691
AB - Background/purpose In Asia, oral squamous cell carcinoma (OSCC) are on the rise in part due to the consumption of betel nut in several regions. This clinical case study evaluated the application of the microtube array membrane-hollow fiber assay (MTAM-HFA) that was previously clinically demonstrated in the context of the selection of chemotheraputic agents as part of the treatment of concurrent chemoradiotherapy (CCRT) in OSCC.Materials and methods In this double-blind cohort study, surgical samples from OSCC patients were retrieved and sent for screening of tumor response against a panel of chemotherapeutic agents (5-fluorouracil (5-FU), cisplatin, carboplatin and docetaxel). Screening outcomes were compared to the clinical outcome of patients receiving the same agents.Results MTAM-HFA could predict clinical response of all 3 patients. In patient 1 and 2, MTAM-HFA screening predicted the chemotherapeutic agents accurately which was reflected in the clinical outcome of these respective patients where a significant and stable regression of tumor was observed. In patient 3, the MTAM-HFA screening revealed that 5-FU and cisplatin would exhibit limited anticancer effect. Clinically, after being administered a cocktail of docetaxel, cisplatin and 5-FU, the tumor regressed initially. However, tumor progression was noted after 2nd neoadjuvant chemotherapy. Anticancer drug resistance was later identified resulting in the need for multimodal approach.Conclusion Overall, the outcomes were aligned with MTAM-HFA predictions, validating the ability to predict the anti-cancer effects of drugs. This highlights MTAM-HFA as a promising precision oncology system; with a larger prospective interventional clinical study planned for future validation.
SN - 1991-7902
SN - 2213-8862
ER -